A study to investigate the potential for AZD5672 to affect the electrical conduction pathways in the heart

Study identifier:D1710C00006

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Single-centre, Double-blind, Double-dummy, Randomised, Placebo-controlled, Four-period Crossover Study to Assess the Effect of Single Oral Doses of AZD5672 (600 mg and 150 mg) on QT/QTc Interval, Compared to Placebo, using Moxifloxacin (Avelox®) as a Positive Control, in Healthy Male Volunteers

Medical condition

Rheumatoid Arthritis

Phase

Phase 1

Healthy volunteers

Yes

Study drug

AZD5672, Moxifloxacin, placebo

Sex

Male

Actual Enrollment

64

Study type

Interventional

Age

18 Years - 45 Years

Date

Study Start Date: 01 Apr 2009
Primary Completion Date: -
Study Completion Date: 01 Jul 2009

Study design

Allocation: Randomized
Endpoint Classification: Pharmacodynamics Study
Intervention Model: Crossover Assignment
Masking: Double Blind
Primary Purpose: Basic Science

Verification:

Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

Quintiles Limited

Inclusion and exclusion criteria